Next Article in Journal
Multiple Remissions of Extracavitary Primary Effusion Lymphoma Treated With a Single Cycle of Liposomal Doxorubicin in a Patient Infected With HIV
Previous Article in Journal
Use of Targeted Therapy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Economic Impact in a Canadian Real-Life Setting
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Anti-Yo Antibody–Mediated Paraneoplastic Cerebellar Degeneration Associated with Cognitive Affective Syndrome in a Patient with Breast Cancer: A Case Report and Literature Review

1
Department of Medicine, University of Ottawa, 501 Smyth Road, Room C2321, Ottawa, ON K1H 8L6, Canada
2
Department of Medicine, Division of Medical Oncology, University of Ottawa, Ottawa, ON K1H 8L6, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2018, 25(6), 585-591; https://doi.org/10.3747/co.25.4106
Submission received: 8 September 2018 / Revised: 9 October 2018 / Accepted: 11 November 2018 / Published: 1 December 2018

Abstract

Breast cancer is the most common cancer in women, with 15%–25% of those tumours overexpressing the human epidermal growth factor receptor 2 (her2), which is associated with more aggressive disease. On rare occasions, patients present with a paraneoplastic syndrome months to years before their cancer diagnosis. Paraneoplastic cerebellar degeneration (pcd) is associated with fewer than 1% of cancers and is strongly associated with breast and gynecologic malignancies. Anti-Yo antibody is the antibody most frequently identified with the syndrome, and it is associated with a very poor prognosis. Recent studies have implicated a relationship between overexpression of her2 and anti-Yo–mediated pcd. Current pcd treatments include tumour removal, chemotherapy, targeted therapy, and immune-suppressive treatments. Outcomes of pcd are typically poor, and no guidelines for treatment currently exist. Early recognition followed by rapid initiation of treatment remains the cornerstone of therapy.
Keywords: paraneoplastic syndrome; her2; anti-Yo antibody; breast cancer; cerebellar degeneration; cognitive affective syndrome paraneoplastic syndrome; her2; anti-Yo antibody; breast cancer; cerebellar degeneration; cognitive affective syndrome

Share and Cite

MDPI and ACS Style

Le May, M.; Dent, S. Anti-Yo Antibody–Mediated Paraneoplastic Cerebellar Degeneration Associated with Cognitive Affective Syndrome in a Patient with Breast Cancer: A Case Report and Literature Review. Curr. Oncol. 2018, 25, 585-591. https://doi.org/10.3747/co.25.4106

AMA Style

Le May M, Dent S. Anti-Yo Antibody–Mediated Paraneoplastic Cerebellar Degeneration Associated with Cognitive Affective Syndrome in a Patient with Breast Cancer: A Case Report and Literature Review. Current Oncology. 2018; 25(6):585-591. https://doi.org/10.3747/co.25.4106

Chicago/Turabian Style

Le May, M., and S. Dent. 2018. "Anti-Yo Antibody–Mediated Paraneoplastic Cerebellar Degeneration Associated with Cognitive Affective Syndrome in a Patient with Breast Cancer: A Case Report and Literature Review" Current Oncology 25, no. 6: 585-591. https://doi.org/10.3747/co.25.4106

APA Style

Le May, M., & Dent, S. (2018). Anti-Yo Antibody–Mediated Paraneoplastic Cerebellar Degeneration Associated with Cognitive Affective Syndrome in a Patient with Breast Cancer: A Case Report and Literature Review. Current Oncology, 25(6), 585-591. https://doi.org/10.3747/co.25.4106

Article Metrics

Back to TopTop